Title of article :
Molecular Status of BRAF Mutation in Prostate Adenocarcinoma: The Analysis of 100 Cases in North-East of IRAN
Author/Authors :
Jafarian, Amir Hossein Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Mirshekar Nasirabadi, Khatoone Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Etemad, Sare Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Jafaripour, Masoumeh Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Darijani, Mansoore Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Sheikhi, Maryam Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Ayatollahi, Hossein Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Shakeri, Sepideh Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Shams, Fatemeh Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran , Davari, Saeed Cancer Molecular Pathology Research Center - Mashhad University of Medical Sciences - Mashhad, Iran
Pages :
7
From page :
415
To page :
421
Abstract :
BRAF mutations were studied in various populations for prostate carcinoma (PC); however, mutations in BRAF gene are unusual compared to KRAS. Oncogenic activating of BRAF mutations were studied lately in almost 0%- 10% of prostate cancer cases. Methods: In this retrospective study, we gathered 100 formalin-fixed paraffin-embedded samples of prostate adenocarcinoma. A hundred archived samples of adjacent benign prostatic hyperplasia were chosen as normal control. This study was done in pathology laboratory of Qaem Hospital during 2013-2015. Results: Total number of 200 PC and normal cases was investigated for BRAF V600E mutation. The BRAF V600E mutation was found in only 4 patients but it was not detected in normal cases. There were no significant differences between patient and control groups for this mutation (P>0.99). The frequency of BRAF V600E mutation was not significant in different age groups (P>0.285); the most frequency was related to the age range of 71-80. No significant difference was observed between tumor grade and BRAF mutation (P=0.21). Conclusion: According to our findings, BRAF gene mutations did not play essential role in PC. Therefore, anti-BRAF (V600E) could not be considered as a proper target for therapy.
Keywords :
Gleason score , Prostate adenocarcinoma , BRAF mutation
Journal title :
Astroparticle Physics
Serial Year :
2018
Record number :
2481535
Link To Document :
بازگشت